BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/18/2026 3:45:45 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-06-01 08:08 |
|
Peer-Review Started |
|
2026-06-01 08:08 |
|
First Decision by Editorial Office Director |
|
2026-06-15 07:35 |
|
Return for Revision |
|
2026-06-15 07:35 |
|
Revised |
|
2026-06-15 11:47 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-08-07 02:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-08-10 10:21 |
|
Articles in Press |
|
2026-08-10 10:21 |
|
Edit the Manuscript by Language Editor |
|
2026-08-14 02:56 |
|
Typeset the Manuscript |
|
2026-08-31 06:38 |
|
Publish the Manuscript Online |
|
2026-09-18 03:45 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the editor: Serum S100A6 as complementary biomarker for pancreatic cancer-an advance needing clearer delineation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chun-Xiao Ni and Jia-Ju Xu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jia-Ju Xu, MD, Department of Medical Oncology, Tai’an City Central Hospital, No. 29 Longtan Road, Tai’an 271000, Shandong Province, China. jiajuxu1101@163.com |
| Key Words |
S100A6; Pancreatic cancer; Early detection; CA19-9; Complementary biomarker; Chronic pancreatitis; Lewis antigen; External validation; Decision curve analysis |
| Core Tip |
This letter commends the innovative study by Bae et al as the first large prospective study evaluating serum S100A6 for early detection of pancreatic cancer, and outlines five points requiring attention. The “early-stage” group consists predominantly of stage II; absence of Lewis antigen status information limits mechanistic understanding of S100A6’s complementary role; single center design and use of historical samples limit generalizability; absence of decision curve analysis means net benefit is unassessed; and how S100A6 enters the circulation is unidentified. Overall, serum S100A6 is promising, but these limitations must be addressed before clinical implementation. |
| Publish Date |
2026-09-18 03:45 |
| Citation |
Ni CX, Xu JJ. Letter to the editor: Serum S100A6 as complementary biomarker for pancreatic cancer-an advance needing clearer delineation. World J Gastroenterol 2026; 32(41): 123870
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i41/123870.htm |
| DOI |
https://doi.org/10.3748/wjg.123870 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
